IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1882
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$136M
Snehal S. Patel
Greenwich LifeSciences focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$GLSI Greenwich LifeSciences, Inc. | 51 | 25 | 41 | 88 | - | - | -645.5% | -370.5% | - | - | - | - | 0.0% | 74.0x | $136M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Greenwich LifeSciences, Inc. (GLSI) receives a "Hold" rating with a composite score of 50.8/100. It ranks #1882 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Snehal S. Patel
Chief Executive Officer
Labor Force
3
25
25
42
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for GLSI
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for GLSI.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 25 | 4 | +21ALPHA |
| MOMENTUM | 88 | 93 | -5NEUTRAL |
| VALUATION | 41 | 19 | +22ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 42 | 21 | +21ALPHA |
| SHORT INT | 82 | 92 | -10DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -645.5% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 6yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns Greenwich LifeSciences, Inc. a Hold rating, with a composite score of 50.8/100 and 3 out of 5 stars. Ranked #1882 of 7,333 stocks, GLSI presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
GLSI's quality score of 25/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -645.5% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 41/100, GLSI appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 152.56x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Greenwich LifeSciences, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -370.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
GLSI shows strong momentum characteristics with a score of 88/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth data is not currently available, while a beta of 1.13 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
GLSI's stability score of 42/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.13 and a debt-to-equity ratio of 74.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
GLSI's short interest factor score of 82/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 74.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $136M, Greenwich LifeSciences, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Greenwich LifeSciences, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1882 of 7,333 overall (74th percentile). Key comparisons include ROE of -645.5% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While GLSI currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (88) vs Quality (25) — closing this gap could shift the rating.
ROE 25929% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 36900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Greenwich LifeSciences, Inc. (GLSI) as a Hold with a composite score of 50.8/100 at a current price of $24.90. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in momentum (88th percentile) and stability (42th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (25th percentile) and investment (25th percentile) tempers our overall conviction. We assign a No Moat rating (19/100), High uncertainty, and Poor capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Greenwich LifeSciences, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 50.8/100 places it at rank #1882 in our full 7,333-stock universe. At $136M in market capitalization, Greenwich LifeSciences, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (88th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Greenwich LifeSciences, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $24.90, Greenwich LifeSciences, Inc. is trading near fair value based on current fundamentals. Our value factor score of 41/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 152.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Positive momentum (88th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
Below-average quality (25th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Elevated short interest (82th percentile) indicates that sophisticated market participants are betting against the stock.
We assign a High uncertainty rating to Greenwich LifeSciences, Inc.. Key risk factors include weak quality scores (25th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: weak quality scores (25th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 42th percentile and quality factor at the 25th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Greenwich LifeSciences, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-645.5%), weak asset returns (ROA -370.5%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Greenwich LifeSciences, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Greenwich LifeSciences, Inc. receives a Hold rating with a composite score of 50.8/100 (rank #1882 of 7,333). Our quantitative framework assigns a No Moat (19/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 44/100.
Our analysis supports a neutral stance on Greenwich LifeSciences, Inc.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Greenwich LifeSciences, Inc. a meaningful economic moat, scoring 19/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (6.9/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of Greenwich LifeSciences, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Greenwich LifeSciences, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 25/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -645.5% and ROA of -370.5%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -645.5% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 74%. The sector median D/E is 0%, putting Greenwich LifeSciences, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Greenwich LifeSciences (Nasdaq: GLSI) announced the acceptance of two abstracts and two posters for presentation at the AACR Annual Meeting 2026. These presentations will detail updates on its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. Notably, one of the accepted abstracts represents the first co-authorship involving the company and the full FLAMINGO-01 steering committee.
Greenwich LifeSciences (NASDAQ:GLSI) saw its stock surge by 54% after the FDA approved the use of its first commercially manufactured GP2 lot for the FLAMINGO-01 Phase III clinical trial. This approval represents a significant step towards de-risking the Biologics License Application (BLA) filing in the US. The company plans to deploy these new GP2 vials to all 40 U.S. trial sites in the coming weeks, while also seeking regulatory approvals in Europe, the UK, and Canada.
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel recently acquired 1,800 shares of the company's stock for approximately $53,694, increasing his total direct ownership to over 5.6 million shares. This purchase is part of a series of insider buys by Patel, further solidifying his stake in the clinical-stage biotechnology company which focuses on immune modulators for cancer and autoimmune diseases. Despite a consensus "Hold" rating from analysts, the company's stock has seen significant movement, with a market cap of $405.7 million and a one-year trading range of $7.78 to $32.91.
Snehal Patel, CEO of Greenwich LifeSciences (NASDAQ:GLSI), recently purchased US$92k worth of shares at US$21.36. This is considered a positive sign, especially since the purchase price was above the current share price of US$20.53, suggesting insider confidence. Insiders hold a significant 53% ownership in the company, worth about US$155m, further indicating alignment with shareholder interests despite the company currently making losses.
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel recently acquired 2,900 shares of the company's stock for $21.73 per share, increasing his total holdings to over 5.59 million shares. This latest purchase, part of a series of insider buys, brings the total value of his stake to approximately $121.6 million. The company's stock trades well above its 50- and 200-day moving averages, and analysts have mixed ratings, although HC Wainwright upgraded it to a "Buy" with a $50 price target.